By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


BioNumerik Pharmaceuticals, Inc. 

8122 Datapoint Drive

San Antonio  Texas  78229  U.S.A.
Phone: 210-614-1701 Fax: n/a



Company News
Lantern Pharma Announces Transaction To Evaluate BioNumerik Pharmaceuticals, Inc.’s Tavocept 8/8/2016 9:53:19 AM
BioNumerik Pharmaceuticals, Inc. Appoints Steve Carchedi to Board of Directors 6/14/2012 11:04:13 AM
BioNumerik Pharmaceuticals, Inc. Initiates Treatment of Patients in Global Phase III Clinical Trial of Tavocept(TM) 1/21/2010 9:22:49 AM
BioNumerik Pharmaceuticals, Inc. Observes Evidence of a Survival Increase in Lung Cancer Patients Participating in Tavocept(TM) Clinical Trial 7/17/2008 6:25:19 AM
BioNumerik Pharmaceuticals, Inc. and ASKA Pharmaceutical Announce Results from Phase III Clinical Trial of Tavocept(TM) 3/18/2008 7:26:03 AM
BioNumerik Pharmaceuticals, Inc. Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R) 2/7/2008 7:26:00 AM
The Day In Review: Nuvelo, Inc. (NUVO) Expands Archemix Corporation Deal 8/1/2006 6:11:15 PM
Takeda Pharmaceutical Co. Ltd. (TKDG.DE) And BioNumerik Pharmaceuticals, Inc. Announce Results Of Tavocept(TM) Phase III Trials Focused On Neuropathy Indication - Trials Did Not Meet Their Primary Endpoints 7/31/2006 5:58:22 PM
BioNumerik Pharmaceuticals Sets IPO At 5 Million Shares, $14-$1610/19/2005 5:11:50 PM
Takeda Pharmaceutical Co. Ltd. (TKDG.DE) Announces Partnership With BioNumerik Pharmaceuticals To Market Tavocept(TM), Phase 3 Chemoprotective Agent, In North America10/19/2005 5:11:47 PM